Unknown

Dataset Information

0

GTP hydrolysis is modulated by Arg34 in the RASopathy-associated KRASP34R.


ABSTRACT: RAS proteins are commonly mutated in cancerous tumors, but germline RAS mutations are also found in RASopathy syndromes such as Noonan syndrome (NS) and cardiofaciocutaneous (CFC) syndrome. Activating RAS mutations can be subclassified based on their activating mechanisms. Understanding the structural basis for these mechanisms may provide clues for how to manage associated health conditions. We determined high-resolution X-ray structures of the RASopathy mutant KRASP34R seen in NS and CFCS. GTP and GDP-bound KRASP34R crystallized in multiple forms, with each lattice consisting of multiple protein conformations. In all GTP-bound conformations, the switch regions are not compatible with GAP binding, suggesting a structural mechanism for the GAP insensitivity of this RAS mutant. However, GTP-bound conformations are compatible with intrinsic nucleotide hydrolysis, including one that places R34 in a position analogous to the GAP arginine finger or intrinsic arginine finger found in heterotrimeric G proteins, which may support intrinsic GTP hydrolysis. We also note that the affinity between KRASP34R and RAF-RBD is decreased, suggesting another possible mechanism for dampening of RAS signaling. These results may provide a foothold for development of new mutation-specific strategies to address KRASP34R -driven diseases.

SUBMITTER: Bera AK 

PROVIDER: S-EPMC7495839 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

GTP hydrolysis is modulated by Arg34 in the RASopathy-associated KRAS<sup>P34R</sup>.

Bera Asim K AK   Lu Jia J   Lu Chunya C   Li Lianbo L   Gondi Sudershan S   Yan Wei W   Nelson Andrew A   Zhang Goujun G   Westover Kenneth D KD  

Birth defects research 20200318 10


RAS proteins are commonly mutated in cancerous tumors, but germline RAS mutations are also found in RASopathy syndromes such as Noonan syndrome (NS) and cardiofaciocutaneous (CFC) syndrome. Activating RAS mutations can be subclassified based on their activating mechanisms. Understanding the structural basis for these mechanisms may provide clues for how to manage associated health conditions. We determined high-resolution X-ray structures of the RASopathy mutant KRAS<sup>P34R</sup> seen in NS an  ...[more]

Similar Datasets

| S-EPMC6825300 | biostudies-literature
| S-EPMC7241937 | biostudies-literature
| S-EPMC1863566 | biostudies-literature
| S-EPMC3439930 | biostudies-literature
| S-EPMC7018511 | biostudies-literature
| S-EPMC5485061 | biostudies-literature
| S-EPMC3561337 | biostudies-literature
| S-EPMC3642159 | biostudies-literature
| S-EPMC8161693 | biostudies-literature
| S-EPMC2785744 | biostudies-literature